Ibrance is indicated for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.1

Dosing

Tablets Capsules



​​​​​​​IBRANCE has a one pill once a day regimen, regardless of dose strength
1

Adapted from IBRANCE Summary of Product Characteristics.1
​​​​​​​
Only 7 capsules per week, 21 capsules in total per month1
IBRANCE recommended dose modification for AEs1
​​​​​​​
​​​​​​​

Adapted from IBRANCE Summary of Product Characteristics.1
​​​​​​​​​​​​​​
*If further dose reduction below 75 mg/day is required, discontinue the treatment.
​​​​​​​
  • Dose reductions or dose modifications due to any AE occurred in 34.4% of patients receiving IBRANCE in randomised clinical studies regardless of the combination1


​​​​​​​
​​​​​​​

AE = adverse event; AI = aromatase inhibitor; IM = intramuscular; PO = orally
​​​​​​​

References

  1. IBRANCE® (Palbociclib) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12240. Accessed September 17, 2021.

Support and Services


Learn more ► 
Learn more ► 
Learn more ► 
All rights reserved. Date of preparation: June 2020 PP-IBR-GLB-0254

​​​​​​​Intended for Healthcare Professionals only.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.